The transcription factor NF-kB is normally sequestered in the cytoplasm by its inhibitory subunit IkB. Most extracellular signals activate NF-kB through a mechanism involving the phosphorylation and proteasomedependent degradation of IkB. EGF activates NF-kB in A-431 carcinoma cells, which overexpress EGF receptors and in mouse embryo ®broblasts, which have a normal complement of receptors. Supershift experiments indicate that the NF-kB complexes induced by EGF are composed of p50/p50 homodimers and p65/p50 heterodimers, but not c-rel. EGF stimulation enhances the degradation of IkBa, but not IkBb nor an N-terminal deletion mutant of IkBa. Treatment of cells with a proteasome inhibitor, such as ALLN or MG132, blocks EGF-mediated NF-kB activation, indicating that EGFinduced NF-kB activation requires proteasome-dependent IkB degradation. Also, Bapta A/M (a cell-permeable chelator of intracellular calcium) blocks EGF-induced NF-kB activation and IkBa degradation, suggesting a requirement of intracellular free Ca 2+ for this growth factor response. Protein kinase C inhibition, in contrast, did not in¯uence EGF activation of NF-kB.
Introduction
Epidermal Growth Factor (EGF) exhibits a variety of biological activities, both mitogenic and non-mitogenic, in cell culture systems as well as the intact animal (Carpenter and Wahl, 1990; Fisher and Lakshamanan, 1990) . These biological responses are mediated through the binding of EGF to its speci®c receptor and enhanced receptor tyrosine kinase activity. Various intracellular signaling pathways are subsequently activated with tyrosine phosphorylation serving as the initial biochemical step (Carpenter, 1993) .
Certain intracellular signaling elements lead to the activation of transcription factors and the expression of new gene products to mediate dierent physiological responses. EGF was previously shown to induce STAT 1a/1b, STAT 3 and STAT 5 in both A-431 cells and mouse liver extracts through direct tyrosine phosphorylation (Ru-Jamison et al., 1993; 1995) . In addition, EGF can also induce several transcription factors involved in mitogenic activities, such as activator protein 1 (AP-1) and activating transcription factor-2 (ATF-2) (Cochran et al., 1984; Hu et al., 1994; Wilhelm et al., 1995) . The role of nuclear factor-kB (NF-kB) in cell growth is not well understood (Baeuerle and Henkel, 1994; Siebenlist et al., 1994) . However, EGF induces the expression of many genes involved in cell growth and some of these (e.g c-myc, E-selectin and Cox-2) contain NF-kB promoter binding sites (Duyao et al., 1990; La Rosa et al., 1993; Ji et al., 1994; Schmedtje et al., 1997) . The capacity of EGF and other growth factors to activate NF-kB has not been well studied. Previously, EGF has been shown to activate NF-kB in rat aortic smooth muscle cells (Obata et al., 1996) , but not in human microvascular endothelial cells (Izumi et al., 1994) . That NF-kB may have a role in mitogenic signaling is suggested by reports showing that oncogenic forms of Ha-Ras or Raf-1 activate reporter genes controlled by NF-kB sites (Finco and Baldwin, 1993; Galang et al., 1994; Finco et al., 1997) . Also, decreased IkBa levels enhance cell transformation (Beauparlant et al., 1994) and expression of dominant interfering IkBa mutants block Ha-Ras transformation (Finco et al., 1997) . EGF-dependent mitogenesis involves the activation of cellular Ras and Raf.
NF-kB is either a homodimer or a heterodimer composed with ®ve NF-kB family members: p50, p52, p65, c-rel, and rel B (Baeuerle and Henkel, 1994; Siebenlist et al., 1994) . The NF-kB complex is normally sequestered in the cytoplasm by direct association with its inhibitory subunit IkB (Thanos and Maniatis, 1995; Baeuerle and Baltimore, 1996) . Stimuli such as tumor necrosis factor a (TNFa), interleukin 1 (IL-1), 12-0-tetradecanoyl-13-phorbol acetate (TPA), and lipopolysaccharide (LPS), lead to the phosphorylation of the inhibitor of kB (IkBa) molecule on serine residues 32 and 36. Following phosphorylation, IkBa is ubiquitinated and degraded by a proteasome-dependent mechanism. NF-kB then translocates to the nucleus. A recent study indicated that pervanadate, a tyrosine phosphatase inhibitor, activates NF-kB through the IkBa tyrosine phosphorylation on tyrosine residue 42 (Imbert et al., 1996) . This tyrosine phosphorylation dissociates IkBa from NF-kB but does not lead to degradation of IkBa. In this report, the capacity of EGF to induce NF-kB activation in cell lines commonly used for signal transduction studies is documented and elements of the mechanism are described. activity was measured following EGF treatment of human carcinoma A-431 cells, which overexpress EGF receptors (2.0610 6 receptors per cell) (Haigler et al., 1978) and mouse embryo ®broblasts (MEF), which express a more normal level of receptors (5.0610 4 receptors per cell) (J Baulida and G Carpenter, unpublished results) . As demonstrated by electrophoretic mobility shift (EMS) assays in Figure 1 , EGF addition to A-431 cells induced two shifted complexes with an oligonucleotide probe containing the NF-kB binding site. Compared to unstimulated A-431 cells, EGF most dramatically induced the slow-migrating complex, but also enhanced the fast-migrating complex. This occurred in a time-dependent manner and was ®rst detectable at approximately 15 min following growth factor addition and was maximal at about 1 h. In contrast, the NF-kB activity induced in MEF by EGF is much more transient. These kinetic dierences tend to parallel the dierences in receptor autophosphorylation kinetics following EGF addition. EGF produces a prolonged tyrosine phosphorylation of the EGF receptor in A-431 cells, but rapid and very transient receptor tyrosine phosphorylation in MEF (data not shown).
To determine whether or not the EGF-induced NF-kB complexes are speci®c, a competition experiment was performed using A-431 nuclear extract obtained from cells treated without or with EGF for 1 h. As shown in Figure 2 , addition of a 50-fold molar excess of unlabeled NF-kB binding site probe (lane 2) completely abolished NF-kB binding activity. In contrast, binding site probes for AP-1 (lane 3) or Oct-1 (lane 4) did not in¯uence factor binding. These data indicate that the EGF-induced gel shift complexes are NF-kB speci®c.
The NF-kB family member is composed of several proteins, including p50 p52, p65 (rel A), c-rel and rel B (Baeuerle and Henkel, 1994; Siebenlist et al., 1994) . The active forms of NF-kB are normally referred to as p65/ p50 heterodimers or p50 heterodimers with other NF-kB family members (Baeuerle and Henkel, 1994; Siebenlist et al., 1994) . To determine which NF-kB subunits are present in the two shifted complexes induced in A-431 cells by EGF, a supershift experiment was performed using speci®c antibodies against p50, p65 and c-rel (Figure 2 ). The p50 antibody completely supershifted both the fast and slow migrating NF-kB complexes (lane 7). The p65 antibody only supershifted the slow migrating complex (lane 8) while the c-rel antibody had no eect on either NF-kB complexes (lane 9). These results indicated that, in A-431 cells, EGF induces p65/ p50 hetero-and p50/p50 homodimers.
EGF and IkBa degradation
The two previously identi®ed mechanisms to activate NF-kB involve the dissociation of IkB. In most instances, agonists provoke serine phosphorylation of IkBa, which leads to its dissociation from NF-kB and is followed by the rapid degradation of phosphorylated IkBa (Thanos and Maniatis, 1995; Baeuerle and Baltimore, 1996) . A recent report, however, showed that pervanadate, a tyrosine phosphatase inhibitor, could dissociate IkBa from NF-kB by increasing the tyrosine phosphorylation of IkBa (Imbert et al., 1996) . As the initial biochemical step in EGF signaling is the activation of receptor tyrosine kinase activity, either or both of the above activation mechanism for NF-kB might apply.
To determine how EGF treatment alters the IkBa subunit, A-431 cells were stimulated with EGF and cell extracts, prepared at dierent time points, were assayed for tyrosine phosphorylation or degradation of IkBa. Immunoblots with anti-phosphotyrosine failed to detect the presence of phosphotyrosine on IkBa (data not shown). However, EGF was found to induce IkBa degradation, as shown in Figure 3a . Since NF-kB activation increases expression of mRNA for IkB (Sun et al., 1993) , cycloheximide was employed in this experiment to prevent the synthesis of new IkB molecules during treatment with EGF. Densitometric analysis indicates that 95% of the cellular pool of IkBa was degraded following a 2 h incubation with EGF Aliquots of nuclear extracts (10 mg) from EGF-treated A-431 cells were incubated for 30 min at room temperature with, as indicated, no antibody or 1.0 ml each of normal rabbit serum, p50 antibody, p65 antibody, or c-rel antibody (lanes 5 ± 9). Parallel aliquots (10 mg) were tested for oligonucleotide speci®city (lanes 1 ± 4) by adding, as indicated, no competitor, or a 50-fold molar excess of unlabeled probes for NF-kB, AP-1 or Oct-1, prior to the addition of the 32 P-labeled NF-kB probe (50 000 c.p.m). EMS assays were performed as described in Materials and methods. The interactions of antibodies with protein:DNA complexes are indicated by a supershifted signal (Figure 3b ). To be sure that cycloheximide did not, by itself, provoke IkBa degradation and to test the in¯uence of EGF on the metabolic turnover of IkBb, the experiment shown in Figure 4 was performed. These data demonstrate that IkBb degradation is not produced by EGF and that cycloheximide exposure does not account for the EGF-induced degradation of IkBa. In this experiment, following a 2 h incubation, EGF produced a 95% decrease of IkBa in the presence of cycloheximide, while cycloheximide alone resulted in no detectable loss of IkBa over the same period of time.
Agonist-dependent degradation of IkBa is mediated through phosphorylation of Ser 32 and Ser 36 and deletion of the IkB N-terminus prevents agonistinduced degradation of IkBa (Thanos and Maniatis, 1995; Baeuerle and Baltimore, 1996) . Therefore, EGF was tested for its capacity to signal degradation of an IkBa N-terminal truncation mutant, IkBa DN37, in which residues 1 ± 37 have been deleted (Brockman et al., 1995) . Cos-6 cells were transiently transfected with an expression vector containing sequences for either the full-length or truncation mutant IkBa. The cells were pretreated 30 min with cycloheximide and then stimulated for the indicated times with either TPA plus ionomycin or EGF. The amounts of full-length and mutant IkBa were then determined by Western analysis. Treatment with TPA and ionomycin has been shown to stimulate degradation of IkBa following phosphorylation at Ser 32 and 36 (Brockman et al., 1995) . As shown by the data in Figure 5 , EGF induced substantial degradation of full-length IkBa (lane 5), which was comparable to the level of degradation induced by TPA and ionomycin (lane 3). In contrast, the N-terminal truncated IkBa was resistant to degradation induced by either TPA and ionomycin or EGF. These results show that the EGF-mediated degradation of IkBa requires the N-terminus and probably serine phosphorylation.
The degradation of phosphorylated IkBa is mediated through ubiquitination and proteasome activity. Proteasome inhibitors, such as N-acetyl-L-leucinyl-Lleucinyl-L-norleucinal (ALLN) or MG132, were previously shown to block NF-kB activation induced by various stimuli (Thanos and Maniatis, 1995) . Since the above data indicate that EGF induces NF-kB activation and the degradation of IkBa, proteasome inhibitors were tested for their capacity to block EGFdependent IkBa degradation and the NF-kB activity. A-431 cells were pretreated with ALLN or MG132 to block proteasome activity and NF-kB DNA binding activity was then examined in the absence or presence of EGF. As shown in Figure 6a , EMS assays demonstrate that treatment with either proteasome inhibitor markedly attenuates EGF-induced NF-kB activity (lanes 5 and 6). Treatment with ALLN or MG132 alone exert no signi®cant eect on basal NFkB activity.
Previous studies have shown that proteasome inhibitors prevent NF-kB activation by blocking IkBa degradation (Thanos and Maniatis, 1995) . The data presented in Figure 6b indicate that both ALLN (lane 5) and MG132 (lane 6) protect IkB from EGF-induced degradation. In the presence of these proteasome inhibitors we have not detected a band-shifted species of IkBa that is frequently detectable and indicative of phosphorylated IkBa. The reason for this may be technical, i.e. gel systems, or due to a relatively weak phosphorylation of IkBa by EGF. Alternatively, a 5% serum and then pretreated with cycloheximide (10 mg/ml) for 30 min. EGF (100 ng/ml) was then added to the indicated cells. At the indicated times, cell lysates were prepared, resolved on a 10% SDS ± PAGE gel, and proteins transferred to nitrocellulose. Western blotting was then performed with speci®c antibody to IkBa. After visualizing bound anti-IkBa, the blot was stripped, reblotted with antibody to IkBb, and this bound antibody detected. A non-speci®c band obtained with IkBa antibody was employed as a control for equal loading dierent mechanism may be employed by EGF to signal IkBa for degradation that does not produce a high level of IkBa phosphorylation.
Intracellular calcium and EGF activation of NF-kB
The combination of TPA, a protein kinase C (PKC) activator, and ionomycin, an ionophore that raises intracellular Ca 2+ levels, is frequently used to activate NF-kB in dierent cell types. Ligand stimulation of the EGF receptor tyrosine kinase phosphorylates and activates phospholipase C-g1 (PLC-g1) in many dierent cell types (Carpenter, 1993) . Activated PLCg1 hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP 2 ), which generates two intracellular signaling molecules: inositol 1,4,5-trisphosphate induces the mobilization of intracellular Ca 2+ , while diacylglycerol activates PKC.
The following experiment was performed to determine whether the second messenger products of PIP 2 hydrolysis are involved in EGF activation of NFkB. Bapta A/M, a cell permeable calcium chelator, or the speci®c PKC inhibitor GF 109203X were preincubated with the A-431 cells for 30 min followed by the addition of EGF. As shown in Figure 7a , neither Bapta A/M nor GF 109203X exerted a detectable eect on the basal levels of NF-kB activity, as judged by EMS assays. However, Bapta A/M (lane 5), but not GF 109203X (lane 6), inhibited the EGF-induction of both p65/p50 and p50/p50 NFkB complexes. The speci®city of Bapta A/M in the activation of NF-kB by other agonists was measured in A-431 cells treated with TPA or the protein phosphatase inhibitor okadaic acid, which is known to activate NF-kB (TheÂ venin et al., 1990; Sun et al., 1995) . The data (Figure 7b) show that Bapta A/M did block NF-kB activation by TPA (lane 4), but not activation by okadaic acid (lane 6).
To further assess the potential action of intracellular Ca 2+ in this EGF-dependent system, the capacity of Bapta A/M to in¯uence EGF-stimulated degradation of IkBa was assayed. For comparison, the stimulation of IkBa degradation mediated by TPA was assayed. As shown in Figure 8 (a) Cos-6 cells were grown in DMEM medium containing 10% fetal calf serum. After 24 h in culture, 5.0 mg of plasmids encoding either full-length IkBa (pCMV4-IkBa-WT) or a N-terminus truncated form of IkBa (pCMV4-IkBa-DN37) were transfected using DEAE-dextran as described in Materials and methods. The transfected cells were incubated overnight and subcultured. After 12 ± 16 h in culture, the cells were incubated in medium containing 0.5% calf serum for 12 ± 16 h, pretreated for 30 min with cycloheximide (10 mg/ml), and stimulated for 1 h or 2 h with either TPA (50 ng/ml) plus ionomycin (1 mM) or EGF (100 ng/ml). Lysates were prepared and aliquots (100 mg) were separated by SDS ± PAGE and the amount of IkBa was determined by Western blot analysis. 
Discussion
Previously EGF has been demonstrated to activate NF-kB relatively slowly in smooth muscle cells (Obata et al., 1996) . In that study activation was detectable 1 h following EGF addition and was maximal at about 3 h. Similarly, activation of NF-kB was reported also for ®broblast growth factor and platelet-derived growth factor and the predominant species activated was the p65/p50 form of NF-kB. Our data show a similar activation of the p65/p50 form of NF-kB, but with a more rapid time course. Other studies have reported the induction of NF-kB sensitive genes in cells transformed by the cytoplasmic tyrosine kinase v-src (Cabannes et al., 1997) and the oncogenic form of the co-receptor tyrosine kinase ErbB-2 (Galang et al., 1996) . Also, activation of NF-kB has been reported for estrogen receptor negative mammary carcinoma tissue and cell lines (Nakshatri et al., 1997) , which frequently overexpress ErbB receptor tyrosine kinases, particularly the EGF receptor and ErbB-2. However, in these various studies no mechanistic information regarding the signaling transduction pathway(s) that are employed by receptor tyrosine kinases to activate NF-kB have been presented nor has the modulation of IkB by growth factors been described.
In this manuscript, the capacity of EGF to activate NF-kB is demonstrated and aspects of the mechanisms involved are presented. In general, the latter experiments are consistent with the well known mechanism for NF-kB activation by ligands, such as TNF-a, that do not activate receptor or non-receptor tyrosine kinases. This mechanism involves the enhancement of serine phosphorylation at two sites in the N-terminus of IkBa, followed by increased degradation of IkBa. Recently two reports (ReÂ gnier et al., 1997; DiDonato et al., 1997) have identi®ed an IkBa kinase (IKKa) that is likely to be the relevant IkB kinase. Agonists such as TNF, IL-1, and TPA activate a signaling pathway that involves a protein known as NIK (NF-kB inducing kinase) as an upstream and perhaps direct activator of IKKa. However, the capacity of agonists dependent on tyrosine kinases to in¯uence either NIK or IKKa is unknown. Interestingly, phosphorylated IKKa is dephosphorylated by protein phosphatase 2A(PP2A), which is relevant to the reported capacity of okadaic acid to activate NF-kB in intact cells (TheÂ venin et al., 1990; Sun et al., 1995) . Hence, inhibition of phosphatase activation is a potential mechanism for activation of NF-kB, though there are no examples of hormone activation of NF-kB by this route. Lastly, pervanadate is reported to enhance phosphotyrosine on IkBa and thereby lead to NF-kB activation (Imbert et al., 1996) .
The data in this report do not ®nd evidence of tyrosine phosphorylation of IkBa in response to EGF. However, we do ®nd that EGF activation of NF-kB is blocked by Bapta A/M, a chelator of intracellular Ca
2+
. Control experiments show that Bapta A/M does not attenuate growth factor-induced autophosphorylation of the EGF receptor (data not shown). The data in this paper indicate, therefore, that free intracellular calcium is necessary at a post-receptor signaling step for the EGF activation of NF-kB, as measured by DNA-binding activation and the enhancement of IkBa degradation. While Bapta A/M did not block okadaic A-431 cells were incubated overnight in 0.5% serum and then were pretreated with cycloheximide (10 mg/ml) for 30 min in the presence or absence of Bapta A/M (30 mM) or GF109203X (10 mM), prior to the addition of EGF (100 ng/ml) or TPA (50 ng/ml) for 2 h. Western analysis was then performed to determine the amount of IkBa.
The arrows indicate the IkBa band and a non-speci®c band (n.s.)
acid activation of NF-kB, which may indicate a level of speci®city with this inhibitor, the results still need to be interpreted cautiously. It cannot be concluded that EGF receptor-induced phosphorylation and activation of PLC-g1 produce an increase in the level of intracellular free Ca 2+ that is necessary for NF-kB activation. The Bapta A/M block could be due solely to chelation of the low resting levels of intracellular free Ca 2+ , which could be required but not sucient to activate NF-kB.
A recent report has demonstrated in activated B cells that Ca 2+ activation of dierent transcription systems can dier greatly with regard to the amount of free intracellular Ca 2+ required (Dolmetsch et al., 1997) . In that system, NF-kB activation, in contrast to the activation of NFAT (nuclear factor for activation of transcription), required a large increase in intracellular free Ca
, suggesting an active signal, such as PLC activation, for the mobilization of stored Ca
. While free intracellular Ca 2+ has been proposed to have a role in the activation of several transcription factors (Berridge, 1995; Ginty 1997) , the mechanism is only clear for NFAT activation. Though ionomycin, a Ca 2+ ionophore, together with TPA are frequently employed as activators of NF-kB, the role of intracellular Ca 2+ in the activation of this transcription factor is not clear. In fact, treatment of T cells with ionomycin only produces a weak activation of NF-kB, suggesting that intracellular Ca 2+ acts synergistically with the activation of PKC (Baeuerle and Henkel, 1994) . However, when T cells are treated with phytohemagglutinin (PHA), NF-kB is activated in a manner that requires an in¯ux of extracellular Ca 2+ but not PKC activity (Kanno and Siebenlist, 1996) . These authors also report that activated forms of calcineurin and Raf-1 act synergistically in T cells to bring about NF-kB activation.
Similarly, the activation of NF-kB by EGF may require input from Ca 2+ -dependent and Ca
-independent pathways. The latter would not seem to include PKC, however, as inhibition of PKC did not decrease EGF activation of NF-kB. Other growth factor activated signaling components, Raf (Bertrand et al., 1995) , p90 rsk1 (Schouten et al., 1997) , and MEKK-1 (Lee et al., 1997) , have been implicated in NF-kB activation. Also, EGF is reported to generate H 2 O 2 in A-431 cells (Bae et al., 1997) and peroxide and oxidative stress are, in some cells, activators of NFkB (Schmidt et al., 1995) . While serine/threonine kinases and H 2 O 2 formation are activated by EGF, none of these is known to be Ca 2+ dependent. Also, it remains to be seen whether these signaling elements communicate with the recently reported kinases (NIK and IKKa) that phosphorylated IkB in response to some agonists and whether these steps may require a Ca 2+ -dependent component.
Materials and methods

Reagents
EGF was isolated from mouse submaxillary glands as previously described (Savage and Cohen, 1972) . TPA was purchased from Sigma. Ionomycin, ALLN, MG132, and GF 109203X were obtained from Calbiochem. Bapta A/M was purchased from Molecular Probes. Where necessary, stock solutions of each agent were prepared in DMSO. Antibodies to IkBa and IkBb were purchased from Santa Cruz and used at the concentration suggested by manufacturer. PLC-g1 antibody was obtained from Transduction Laboratories and used at a 1 : 1000 dilution. The p50, p65 and c-rel antibodies, plus pCMV4-IkBa(DN37) were generous gifts from Dr Bean Ballard (Vanderbilt University, Nashville, TN) and were previously described (Brockman et al., 1995; Chu et al., 1996) .
Cell culture
Human carcinoma cell lines A-431 cells were maintained in Dulbecco's Modi®ed Eagle's Medium (DMEM) pH 7.4, supplemented with 10% calf serum (Hyclone) and 50 mg/ml of Gentamycin (GIBCO). For most experiments, 5610 5 A-431 cells were subcultured into 60 mm dishes and 48 h later were incubated overnight in DMEM plus 0.5% calf serum (70% con¯uent). Immortalized mouse embryo ®broblasts (MEF) were generated by standard procedures and were previously described . MEF cells were cultured in DMEM medium, pH 7.4, containing 10% fetal calf serum (Hyclone) and 50 mg/ml of Gentamycin (GIBCO). For experiments, 5610 5 MEF were seeded into 100 mm plates and 48 h later were incubated in a medium containing 0.5% fetal calf serum. Cos-6 cells were maintained in DMEM medium containing 10% fetal calf serum and 50 mg/ml of Gentamycin. Cos-6 cells (1.5610 6 ) were subcultured into 100 mm dishes for transient transfection experiments.
NF-kB DNA binding
Nuclear extracts were prepared as previously described (Schreiber et al., 1989) . Brie¯y, cells were washed twice in ice-cold phosphate buered saline (PBS), scrapped into 1.0 ml of PBS, and collected into a microcentrifuge tube by centrifugation (14 000 g, 30 s). Cell pellets were then lysed in Buer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.5% NP-40, 0.1 mM dithiothreitol (DTT), 10 mg/ml leupeptin, 10 mg/ml aprotinin, 1 mM phenylmethylsulfonyl¯uoride (PMSF)), and the nuclei pellets were collected by centrifugation (14 000 g, 30 s). Nuclear extracts were obtained through three cycles of freeze/thaw (dry-ice/378C) in buer B (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA 1 mM DTT, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 1 mM PMSF), and stored at 808C before use. Protein concentrations in the nuclear extract were determined by the method of Bradford using bovine serum albumin as a standard.
The NF-kB mobility shift probe was obtained from the murine IL-2 promoter (5'-AAGAGGGATTTCACCT), and 32 P-radiolabeled with the Klenow-®ll reaction using a-32 PdATP (3000 Ci/mmole, New England Nuclear). The labeled probe was separated from free nucleotides by NICK column (Pharmacia). A 10 mg aliquot of each nuclear extract was incubated with EMS binding buer (20 mM HEPES, pH 7.9, 5% glycerol, 1 mM EDTA, 50 mM KCl, 0.5% NP-40, 1.0 mg of poly(dI/dC), 5 mM DTT) in a total volume of 20 ml for 15 min at room temperature. Approximately 50 000 c.p.m. of 32 P-radiolabeled NF-kB probe was then added, followed by another 20 min incubation at room temperature. The DNA binding complexes were separated on 6% PAGE/16TBE native gel. The gel was dried and exposed to X-ray ®lm at 7808C. In competition experiments, a 50-fold molar excess of unlabeled probe was incubated for 15 min with the extract prior to the addition of the NF-kB radiolabeled probe. For antibody supershift experiments, 1 mC of each antibody (p50, p65, c-rel) or preimmune serum were incubated for 15 min with the nuclear extract before addition of the labeled NF-kB probe.
Western blot
Cells were washed twice with ice-cold PBS then lysed on ice with 250 mC of TGH buer (1% Triton X100, 10% glycerol, 20 mM HEPES, pH 7.2 and 100 mM NaCl, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 1 mM PMSF and 1 mM Na 3 VO 4 ) and transferred to a microcentrifuge tube. Protein extracts were separated from the cell debris by centrifugation (14 000 g, 10 min) at 48C. Equal amounts of protein lysates (100 mg) were resolved on 10% SDS ± PAGE gel, transferred to the nitrocellulose paper for Western blotting. Nitrocellulose membranes were blocked by overnight incubation at 48C in TBST buer (0.1% Tween 20, 150 mM NaCl, 50 mM Tris, pH 7.4) containing 5% non-fat milk, washed, and subsequently incubated with IkBa antibody (1 : 500 dilution) or IkBb antibody (1 : 500 dilution) for 2 h at room temperature with shaking. The membrane was then washed three times in TBST buer incubated with horseradish peroxidase-conjugated donkey anti-rabbit IgG antibody (Amersham), washed in TBST, and visualized by enhanced chemiluminescence (ECL).
Transient transfection
Cos-6 cells were transfected with either pCMV4-IkBa(wt) or pCMV4-IkBa(DN37) using the DEAE-dextran method (ReÂ gnier et al., 1997). Brie¯y, cells (100 mm plates, 70% con¯uent were washed twice with PBS, and cultured with 8 ml of DMEM containing 10% serum and supplemented with 5 mg of each DNA plasmid, plus 100 mM TrisCl, pH 7.3 and 2.5 mg/ml of DEAE-dextran (Pharmacia). After 6 h in culture, cells were washed once with PBS, shocked with 10% DMSO in PBS for 3 min at room temperature, cultured again in 8 ml of 10% DMEM medium containing 0.1 mM chloroquine for 2 h. Cells were then washed twice with PBS, and cultured in 10 ml of complete media for 24 h, followed by subculturing into ®ve 60 mm dishes. The transfected cells were cultured in DMEM with 10% serum for 12 h and starved for 12 h with DMEM plus 0.5% serum. The cells were then pretreated with cycloheximide (10 mg/ml) for 30 min and stimulated with EGF (100 ng/ ml) or TPA (50 ng/ml) plus ionomycin (1 mM). Cell extracts were prepared after 1 or 2 h stimulation and the IkBa protein was examined with Western blotting.
